![Paclitaxel, bevacizumab, and everolimus/placebo as first-line treatment for patients with metastatic HER2-negative breast cancer: a randomized placebo-controlled phase II trial of the Sarah Cannon Research Institute]()
Paclitaxel, bevacizumab, and everolimus/placebo as first-line treatment for patients with metastatic HER2-negative breast cancer: a randomized placebo-controlled phase II trial of the Sarah Cannon Research InstituteYardley, Denise A.; Bosserman, Linda D.; O’Shaughnessy, Joyce A.; Harwin, William N.; Morgan, Susan K.; Priego, Victor M.; Peacock, Nancy W.; Bass, J. David; Burris III, Howard A.; Hainsworth, John D. · Breast Cancer Research and Treatment · 2015